The North America Medical cannabis market Size is valued at USD 5.61 billion in 2023 and is expected to reach USD 15.29 billion by 2028. The medical cannabis market size in North America is projected to grow at a CAGR of 22.23 % from 2023 to 2028.
Public perception and acceptance of medical cannabis have played an important role in the North American Medical Cannabis Market. This has resulted in rising awareness among both patients and healthcare professionals. This evolves the perception of medical cannabis from a stigmatized substance to a therapeutic option, which has significantly expanded the patient seeking its benefits. Many patients who were hesitant about considering it as a viable treatment option have become more open to exploring its potential benefits, particularly for conditions like chronic pain, epilepsy, and anxiety. This change in patient attitudes reflects a growing awareness of the potential therapeutic properties of medical cannabis. Also, it's not just patients who are changing their perspectives; healthcare professionals are also increasingly embracing the idea of incorporating medical cannabis into their treatment options. They've come to recognize that medical cannabis can be an effective tool in alleviating symptoms and enhancing the quality of life for their patients.
The North American Medical Cannabis Market has been influenced by the gradual legalization. This shift has emerged as an important driver of the market expansion. As governments relax regulations and establish clear legal frameworks for medical cannabis, accessibility for patients significantly improves. Legalization has not only licensed the use of medical cannabis but has also fostered a more transparent and regulated marketplace. Patients now have the option to obtain cannabis-based therapies with confidence, knowing that they are compliant with the law and safety standards. This has raised a surge in patient enrolment in medical cannabis programs. Therefore, as provinces continue to refine their regulatory structures, it has covered the way for an expand in industry with new businesses, innovations, and job opportunities. The process has raised market growth by providing patients with alternative therapeutic options and boosting economic growth.
The North American Medical Cannabis Market has a significant restraint from the disparities in pricing that patients encounter based on their geographic location. These price variations are primarily rooted in the diverse regulatory frameworks and tax structures established by individual states and provinces. In some regions, notably those with more stringent regulations or higher taxation on medical cannabis products, patients often find themselves facing significantly elevated costs. These price disparities can have several implications. Also, they create accessibility where patients in higher-cost regions may struggle to afford their necessary medical cannabis treatments. This not only affects the well-being of patients but can also hinder the overall growth and acceptance of medical cannabis as a viable medical option.
Impact of COVID-19 on the North American Medical Cannabis Market:
The COVID-19 pandemic has presented several challenges to the North America Medical Cannabis Market. As lockdowns, social distancing measures, and disruptions in the supply chain temporarily constrained access to medical cannabis products for patients. Dispensaries faced operational challenges, and patients often had to navigate uncertainties in product availability. Economic hardships experienced by many individuals during the pandemic made the high cost of medical cannabis a more significant barrier, limiting patient spending. Over time, the pandemic has also brought about some positive developments in the medical cannabis market. As people endured increased stress and anxiety during the pandemic, the demand for medical cannabis, known for its potential to alleviate mental health symptoms, surged. This rising interest has propelled further research into the therapeutic benefits of cannabis, which could lead to broader acceptance and prescription by healthcare providers. Furthermore, recognizing the importance of essential industries, many regions deemed medical cannabis as an essential service, ensuring continued patient access and bolstering the industry's resilience during times of crisis.
This research report on the North America Medical Cannabis Market has been segmented and sub-segmented into the following categories:
North America Medical Cannabis Market - By Species:
North America Medical Cannabis Market - By Derivatives:
North America Medical Cannabis Market - By Application:
North America Medical Cannabis Market - By End User:
North America Medical Cannabis Market - By Route of Administration:
North America Medical Cannabis Market – By Country:
North America is more by its large patient base, product innovation, and increasing acceptance. However, the regulatory landscape can vary significantly between states and provinces.
The United States holds the largest position in the North America Medical Cannabis Market due to federal restrictions; various states have legalized medical cannabis, contributing to a rapidly growing industry. The U.S. medical cannabis market has benefited from a large patient base and a diverse range of medical conditions eligible for treatment. As legalization efforts gain patients, acceptance is on the rise and is also encouraging medical professionals to explore cannabis-based treatments.
Canada's medical cannabis market is anticipated to show a potential growth rate during the forecast period. The country implemented a federal framework for medical cannabis use by allowing patients with various qualifying conditions to access products through licensed producers. Canada's well-regulated system has raised the confidence of both patients and healthcare providers, and medical cannabis is often covered by insurance plans.
Top Companies leading North America Medical Cannabis Market Profiled in the Report are BOL Pharma, Tilray, Medreleaf Corporation, Aurora Cannabis, Inc., Canopy Growth Corporation, Insys Therapeutics, Inc., Aphria, Inc., MGC Pharmaceuticals Limited, GW Pharmaceuticals, plc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org